Evidence map›Paper›PMID 28634772›Full record

ArticleClinical and experimental nephrology2018

The effect of desensitization therapy in kidney transplantation.

Yong Chul Kim, Mi-Yeon Yu, Jung Pyo Lee, Hajeong Lee, Sang-Il Min, Jongwon Ha, Yon Su Kim

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Landscape of ABO-Incompatible Live Donor Kidney Transplantation in the US.Journal of the American College of Surgeons · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yong Chul KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Mi-Yeon YuDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Jung Pyo LeeDepartment of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Hajeong LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Sang-Il MinDepartment of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
Jongwon HaDepartment of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
Yon Su KimDepartment of Medical Science, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. yonsukim@snu.ac.kr.
Seoul National University Hospital · KRSeoul National University · KRSNUH SMG-SNU Boramae Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDesensitization therapy may enable the patient to get allograft in sensitized recipient or solve the organ shortage in ABO-incompatible relationship in kidney transplantation (KT). However, the graft outcome and morbidity remains unclear.

methodsWe retrospectively analyzed 845 KT patients from January 2010 to February 2016 at Seoul National University Hospital. The patients were divided into three groups as follows: HLA-incompatible (HLAi) group, ABO-incompatible (ABOi) group, and control group. The HLAi group comprised patients who received desensitization therapy due to the presence of donor-specific antibodies (DSAs) or high panel reactive antibodies (PRAs). The ABOi group is defined as those undergoing preoperative desensitization therapy for anti-ABO antibodies.

resultsOf the total of 845 recipients, 48 (5.6%) were HLAi KTs and 71 (13.9%) were ABOi KTs, respectively. Pre-emptive KT is done more frequently in ABOi group, therefore, they had shorter dialysis duration than the others. HLAi recipients had a higher proportion of women than the ABOi group and a higher proportion of re-transplantation. During the 38.4 (0.4-76.9) months of follow-up, there were more acute antibody-mediated rejections (AAMRs) in the HLAi (6.7%) and ABOi (8.5%) groups than in the control group (1.9%) (P = 0.001). However, there was no difference in graft survival, patient survival, and annual allograft among three groups.

conclusionsDespite the higher incidence of AAMRs, HLAi and ABOi KTs showed a favorable graft and patient outcome after desensitization therapy.

Indexed as

Desensitization, ImmunologicABO Blood-Group SystemAdolescentAdultAgedFemaleFollow-Up StudiesGraft RejectionGraft SurvivalHLA AntigensHumansImmunosuppression TherapyKidney NeoplasmsKidney TransplantationMaleMiddle AgedABO Blood-Group SystemHLA AntigensABO-incompatibilityDesensitizationHLA-incompatibilityKidney transplantation

Identifiers

PMID28634772
OpenAlexW2714673966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.